Squamous cell lung cancers (lung squamous cell carcinomas [LUSCs]) are associated with
high mortality and a lack of therapies specific to this disease. Although recurrent molecular …

Lung cancer remains the single deadliest cancer both in the US and worldwide. The great
majority of squamous cell carcinoma (SCC) is attributed to cigarette smoking, which …

Background: The experience of using consolidation durvalumab in post-concurrent
chemoradiation (CCRT) unresectable stage III non-small cell lung cancer (NSCLC) is rare in …

Anecdote clinical observations hint that non‐small cell lung cancer (NSCLC) with exon‐20
insertions might respond poorly to epidermal growth factor receptor (EGFR) tyrosine kinase …

Introduction Squamous-cell carcinoma (SCC) of the lung represents around 20% of non-
small cell lung cancers. Although activating mutations of EGFR are rare in this subtype, its …

We previously reported that although EGFR mutations are not a feature of pure squamous
cell carcinomas (SCC) of the lung, these mutations do occur in adenosquamous carcinomas …

Whether EGFR mutation occurs in lung squamous cell carcinoma (SCC) remains a
controversial issue. Although numerous trials have shown positive response to tyrosine …

The empirical criteria for defining a clinical subtype of lung cancer are gradually transiting
from histopathology to genetic variations in driver genes. Targeting these driver mutations …

Background Although new individual treatments continue to reshape the landscape of
clinical care in patients with lung cancer, most of the progress has been mainly of benefit to …

Epidermal growth factor receptor (EGFR) mutations are common in lung adenocarcinoma
(ADC) but rare in squamous cell carcinoma (SQC). The efficacy of EGFR-tyrosine kinase …